(PharmaNewsWire.Com, June 27, 2017 ) The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
Publishers analysts forecast the global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021. For more information about this report: http://www.reportsweb.com/global-bladder-cancer-therapeutics-market-2017-2021 . Covered in this report The report covers the present scenario and the growth prospects of the global bladder cancer therapeutics market for 2017-2021. To calculate the market size, the report considers the sales from both branded and generic drugs.
The market is divided into the following segments based on geography: Americas APAC EMEA
Publisher's report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors Bristol-Myers Squibb Eli Lilly F. Hoffman-La Roche Pfizer
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
